Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

ClinicalTrials.gov ID: NCT07129252

Public ClinicalTrials.gov record NCT07129252. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 17, 2026, 10:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.

Study identification

NCT ID
NCT07129252
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Enrollment
150 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 25, 2025
Primary completion
Jul 31, 2027
Completion
Jul 31, 2029
Last update posted
Jul 30, 2026

2025 – 2029

United States locations

U.S. sites
23
U.S. states
14
U.S. cities
22
Facility City State ZIP Site status
Crinetics Study Site Phoenix Arizona 85054 Recruiting
Crinetics Study Site Duarte California 91010 Recruiting
Crinetics Study Site Newport Beach California 92663 Recruiting
Crinetics Study Site Orange California 92868 Recruiting
Crinetics Study Site San Francisco California 60637 Recruiting
Crinetics Study Site Aurora Colorado 80045 Recruiting
Crinetics Study Site Denver Colorado 80218 Recruiting
Crinetics Study Site New Haven Connecticut 48201 Recruiting
Crinetics Study Site Atlanta Georgia 30322 Recruiting
Crinetics Study Site Lexington Kentucky 40536 Recruiting
Crinetics Study Site Metairie Louisiana 70006 Recruiting
Crinetics Study Site Detroit Michigan 48201 Recruiting
Crinetics Study Site Grand Rapids Michigan 49503 Recruiting
Crinetics Study Site Rochester Minnesota 53905 Recruiting
Crinetics Study Site New York New York 10016 Recruiting
Crinetics Study Site Philadelphia Pennsylvania 19104 Recruiting
Crinetics Study Site Philadelphia Pennsylvania 19111 Recruiting
Crinetics Study Site Austin Texas 78758 Recruiting
Crinetics Study Site Houston Texas 70030 Recruiting
Crinetics Study Site Irving Texas 75039 Recruiting
Crinetics Study Site Salt Lake City Utah 84112 Recruiting
Crinetics Study Site Charlottesville Virginia 22908 Recruiting
Crinetics Study Site Fairfax Virginia 22031 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07129252, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 30, 2026 · Synced Sep 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07129252 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →